Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Exclusion Criteria

• •1. Presence of - clinically significant lab or ECG results that may affect the evaluation of the efficacy or safety of the study drug at screening visit;
• •2. Uncontrollable hypertension;
• •3. PHQ-9 score ≥15;
• •4. Medical history or illness that affects your weight;
• •5. History of diabetes;
• •6. Acute infection, acute trauma, or medium to large surgery within 1 month prior to screening;
• •7. History of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening;
• •8. Any organ-system malignancies developed within 5 years except for cured local basal cell cancer of the skin and in-situ cancer of the cervix;
• •9. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness;
• •10. History of alcohol and/or substance abuse or drug abuse within 1 year prior to screening;
• •11. Use of any medication or treatment that may have caused significant weight change within 3 months;
• •12. History of bariatric surgery;
• •13. Known or suspected hypersensitivity to trial product(s) or related products;
• •14. Participation in other clinical trials for any weight-loss indication within 3 months prior to screening, or participation in other clinical trials for any drug or medical device within 1 month prior to screening;
• •15. history of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening;
• •16. Surgery is planned during the trial;
• •17. Mentally incapacitated or speech-impaired;
• •18. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method;
• •19. Researchers and relevant staff of the research Centre or other people directly involved in the implementation of the programme, and their immediate family members.